Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Takeda Pharmaceutical Company Limited

< Previous 1 2 3 4 5 Next >
Takeda and HUTCHMED Announce Publication of Phase 3 FRESCO-2 Results in The Lancet
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Present Oncology Portfolio and Pipeline Data at the 2023 ASCO Annual Meeting and EHA Congress
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. Food & Drug Administration Grants Priority Review of TAK-755 for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong Revenue and Profit Growth in FY2022; Updated Capital Allocation Policy Reflects Deleveraging Progress and Confidence in Growth Outlook
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces FDA Acceptance of BLA Resubmission for Investigational Subcutaneous Administration of Entyvio® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Ulcerative Colitis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Receives FDA Approval to Expand the Use of HYQVIA® to Treat Primary Immunodeficiency in Children
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces New U.S. Corporate Social Responsibility (CSR) Program Partners
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Results From Phase 4 Vedolizumab Study in Patients With Chronic Pouchitis Published in New England Journal of Medicine
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Candidates for Board of Directors at Upcoming Shareholders Meeting
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
BioLife Plasma Services Opens its 200th Plasma Donation Center in the U.S.
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Positive Results in Phase 2b Study of Investigational TAK-279, an Oral, Once-Daily TYK2 Inhibitor, in People with Moderate-to-Severe Plaque Psoriasis
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Presents Positive Results from Phase 3 Study of Vedolizumab for Prevention of Intestinal Acute Graft-Versus-Host Disease (aGvHD) in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
U.S. FDA Approves Takeda’s TAKHZYRO® (lanadelumab-flyo) to Prevent Hereditary Angioedema (HAE) Attacks in Children 2 Years of Age and Older
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Reinforces Long-term Growth Through Pipeline Advancement and Two Targeted Acquisitions; Delivers Another Strong Quarter in FY2022 Q3
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda To Acquire Exclusive Worldwide (ex-China) License of HUTCHMED’s Fruquintinib, a Highly Selective, Oral VEGFR1/2/3 Tyrosine Kinase Inhibitor
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Named Global Top Employer for Sixth Consecutive Year
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s EXKIVITY® (mobocertinib) Receives Approval from the NMPA of China, Becoming the First and Only Therapy Available for Patients with EGFR Exon20 Insertion+ NSCLC
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Announces Favorable Phase 3 Safety and Efficacy Results of TAK-755 as Compared to Standard of Care in Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Acquire Late-Stage, Potential Best-in-Class, Oral Allosteric TYK2 Inhibitor NDI-034858 From Nimbus Therapeutics
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda to Present Data at 64th American Society of Hematology (ASH) Annual Meeting, Demonstrating Commitment to Patients with Hematologic Cancers and Other Blood Diseases
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Phase 3 Trial of ICLUSIG® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
European Commission (EC) Approves LIVTENCITYTM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
Takeda Enters Collaboration and Licensing Agreement with Zedira and Dr. Falk Pharma to Develop First-in-Class Celiac Disease Therapy
From Takeda Pharmaceutical Company Limited
Via Business Wire
Tickers TAK
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.